ATRA - atarabio.com Debt to Book Capitalization Ratio

Graphic logo of Atara Bio (ATRA)

European sales and royalties generate a steady cash flow for operational needs. The trajectory of Atara Biotherapeutics' financial leverage clearly demonstrates this resilience, where the level of 0.00 represents the current value. Authority in allogeneic therapy strengthens the position of Atara Biotherapeutics, although the struggle against tech giants for the standard of care in a high-risk sector remains extremely fierce.

ATRA (Atara Bio) Debt to Book Value history from 07/04/2022 to 10/27/2026
Core merchandise of atarabio.com

This ratio is calculated as the proportion of total credit obligations to the organization's equity. The metric determines the issuer's degree of financial autonomy and the level of dependence on external borrowings. For Atara Biotherapeutics (ATRA), a low debt load is critical when undergoing rigorous FDA inspections. This ensures the stability of the Ebvallo platform without the risk of credit pressure. The trend of the financial debt share in the firm's book capitalization reflects the current capital management strategy.

Who Atara Biotherapeutics competes with

Debts to Book Capitalization ARGX (argenx SE)|biontech.de - Debts to Book Capitalization|Debt to Book Capitalization Ratio ABIVAX (ABVX)|ADMA: Debt to Net Assets Ratio|PTGX (Protagonist Therapeutics Inc) - Debt to Book Capitalization Ratio|Immunovant Therapeutics (IMVT) - Debt to Book Value|KNSA (Kiniksa Pharmaceuticals) - Debts to Book Capitalization|Debts to Book Capitalization grifols.com (GRFS)|Adaptive Biotechnologies Corporation (ADPT) - Debt to Book Value|Debt to Net Assets Ratio Celldex Therapeutics Inc (CLDX)|Debts to Book Capitalization AUPH|BioCryst Corp - Debts to Net Assets|VERA: Debt to Book Capitalization Ratio|DNTH: Debt to Book Value|PHVS (Pharvaris) - Debt to Book Capitalization Ratio|Debt to Book Value AbCellera Bio|TRML (Tourmaline Corp) - Debt to Book Value|Debts to Book Capitalization PGEN|Debt to Book Capitalization Ratio Pharming Group N.V. PHAR|Debt to Book Value Ratio nektar.com (NKTR)|UPB: Debts to Book Capitalization|Debts to Book Value Zenas Bio ZBIO|Immunome Corp - Debts to Book Capitalization|Gossamer Bio Corp. (GOSS) - Debts to Book Capitalization|KALV - Debt to Book Value|septerna.com (SEPN) - Debt to Book Capital|PVLA (Pieris Pharmaceuticals, Inc.) - Debts to Book Capitalization|Debts to Book Capitalization SVRA|Rigel Pharmaceuticals Inc (RIGL) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio AnaptysBio Inc. (ANAB)|Debts to Book Capitalization ATXS (Astria Therapeutics)|ENGN - Debts to Book Capitalization|Debt to Book Value RAPT Therapeutics, Inc. (RAPT)|JBIO - Debt to Net Assets Ratio|Aclaris (ACRS) - Debts to Book Capitalization|Kyverna Therapeutics, Inc (KYTX) - Debt to Book Capitalization Ratio|TLSA: Debts to Book Capitalization|Debts to Net Assets CABA|Ventyx Biosciences, Inc. - Debt to Book Capitalization Ratio|Debts to Book Value Theratechnologies, Inc. THTX|Debt to Book Value Avalo Therapeutics Inc. (AVTX)|Debt to Book Capital Eledon Pharmaceuticals, Inc ELDN|Debts to Book Capitalization Agenus (AGEN)|CLYM - Debt to Net Assets Ratio|Debts to Book Capitalization ZURA|ATYR (aTyr Pharma Inc) - Debts to Book Value|ADAG - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio Ikena Oncology, Inc.|Debts to Book Capitalization STTK|Debts to Book Capitalization EQ (equilliumbio.com)|Connect Biopharma Holdings Limited (CNTB) - Debt to Book Capitalization Ratio|Debts to Book Capitalization Ratio Immunic Therapeutics IMUX|IFRX (InflaRx GmbH) - Debts to Book Capitalization|X4 Pharmaceuticals, Inc (XFOR) - Debts to Book Value|ACET: Debt to Book Value|Debts to Book Capitalization Celularity|INmune Bio (INMB) - Debt to Book Value|Debt to Book Capital Barinthus Biotherapeutics PLC|KZR (Kezar Life Sciences, Inc) - Debts to Book Capitalization|Debts to Net Assets SAB Biotherapeutics Inc (SABS)|Akari Therapeutics - Debts to Book Capitalization|Enlivex Therapeutics Ltd - Debt to Book Value|Debt to Book Capitalization Ratio QTTB (Q32 Bio Corp)|GOVX - Debts to Net Assets|EDSA: Debts to Book Capitalization|Debts to Book Capitalization iBio Corporation|Carisma Therapeutics Inc (CARM) - Debt to Book Value|Debt to Book Capital XTLB|Bolt Biotherapeutics (BOLT) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio hcwbiologics.com (HCWB)|Debts to Book Capitalization APVO (Aptevo Therapeutics Inc.)|AIM ImmunoTech, Inc. - Debts to Book Capitalization|Debt to Book Capitalization Ratio Aditxt Corp|GRI - Debts to Book Capitalization Ratio|Debts to Book Capitalization XORTX Therapeutics XRTX|Vyome Holdings Inc. (HIND) - Debt to Net Assets Ratio|REVB (Revelation Bio) - Debts to Book Capitalization|Debts to Book Capitalization INDP|Scinai Immunotherapeutics (SCNI) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio CALI (calcimedica.com)|Affimed N.V. - Debt to Book Capitalization Ratio|Debt to Book Value Allakos Inc ALLK|HOOKIPA - Debts to Book Capitalization|IGM Biosciences, Inc. (IGMS) - Debts to Book Capitalization|Debt to Book Value iTeos Therapeutics ITOS|oceanbiomedical.com (OCEA) - Debt to Net Assets Ratio|TCBP: Debts to Book Capitalization|Debts to Net Assets THRD